On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

Guest Editorial

Preparing to take care of each other in ways we never imagined

Guest Editorial

From the chairs of ECOG-ACRIN: A perspective on indirect costs

White House

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, gender
One month in: Trump’s impact on oncology

Cancer History Project Free Podcast

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

In Brief

Aleksandar Sekulic named physician-in-chief at TGen

Boris Naraev joins TGH Cancer Institute, USF Health

Daniel Nomura named editor-in-chief of Molecular Cancer Therapeutics

Case CCC earns NCI merit award

Children’s National Hospital, Virginia Tech expand partnership for pediatric cancer research

ASCO to recognize 11 Special Awards recipients at the 2025 annual meeting

Drugs & Targets

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approves Gomekli for pediatric patients with neurofiromatosis type 1

EC grants marketing authorization for Removab as a treatment for malignant ascites

Moffitt, 1ST Biotherapeutics collaborate to advance immuno-oncology

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

CHMP recommends approval of Opdivo + Yervoy for unresectable or advanced HCC

In The Clinic

Trials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Trials & Tribulations

Physicians and biopharma should improve accessibility of cancer trials

Trials & Tribulations

From clinician scientist to nonprofit CEO

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

Trials & Tribulations

Chadi Nabhan: Why I wrote a book about cancer

Latest Issue

Read the latest issue

DOWNLOAD THE PDF

NEWS ALERTS

Stay up to date on the latest news in oncology by joining our mailing list.

UPCOMING EVENTS

Mar 2025

NCCN 2025 Annual Conference

Apr 2025

Miami Leukemia Symposium

Cellicon Valley ’25: The Future of Cell and Gene Therapies

May 2025

NCCN Oncology Policy Summit: Primary Care and Oncology Collaboration to Improve Patient Outcomes

2025 ASCO Annual Meeting

View All Events

Conversations with The Cancer Letter

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Brian Druker steps down as CEO of OHSU Knight Cancer Center

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

Contributors

Jim Byron

The War on Cancer: After half a century of progress, a promising prognosis may be Richard Nixon’s greatest legacy

W. Kimryn Rathmell, MD, PhD, MMHC

Communication—We need more, not less

Ruth Fein Revell

World Cancer Day 2025: A symbol of personal and collective uncertainty

City of Hope

At City of Hope, our path to innovation includes surgical simulations in space, diverse genomics data—and more

Trending Stories

Preparing to take care of each other in ways we never imagined
20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research
From the chairs of ECOG-ACRIN: A perspective on indirect costs
What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”
On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

Recent Issues

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

Preparing to take care of each other in ways we never imagined

From the chairs of ECOG-ACRIN: A perspective on indirect costs

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, gender
One month in: Trump’s impact on oncology

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Aleksandar Sekulic named physician-in-chief at TGen

Boris Naraev joins TGH Cancer Institute, USF Health

Daniel Nomura named editor-in-chief of Molecular Cancer Therapeutics

Case CCC earns NCI merit award

Children’s National Hospital, Virginia Tech expand partnership for pediatric cancer research

ASCO to recognize 11 Special Awards recipients at the 2025 annual meeting

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approves Gomekli for pediatric patients with neurofiromatosis type 1

EC grants marketing authorization for Removab as a treatment for malignant ascites

Moffitt, 1ST Biotherapeutics collaborate to advance immuno-oncology

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

CHMP recommends approval of Opdivo + Yervoy for unresectable or advanced HCC

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Physicians and biopharma should improve accessibility of cancer trials

From clinician scientist to nonprofit CEO

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

Chadi Nabhan: Why I wrote a book about cancer

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Brian Druker steps down as CEO of OHSU Knight Cancer Center

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

Jim Byron

W. Kimryn Rathmell, MD, PhD, MMHC

Ruth Fein Revell

City of Hope

Never miss an issue!

Login

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centersThe Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Brian Druker steps down as CEO of OHSU Knight Cancer Center

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

City of Hope

Never miss an issue!

Login

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty